vs
Healthpeak Properties（DOC）与QuidelOrtho Corp（QDEL）财务数据对比。点击上方公司名可切换其他公司
Healthpeak Properties的季度营收约是QuidelOrtho Corp的1.1倍（$702.9M vs $619.8M），Healthpeak Properties净利率更高（51.6% vs -14.8%，领先66.5%），Healthpeak Properties同比增速更快（-6.6% vs -10.5%），过去两年Healthpeak Properties的营收复合增速更高（0.5% vs -6.6%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
DOC vs QDEL — 直观对比
营收规模更大
DOC
是对方的1.1倍
$619.8M
营收增速更快
DOC
高出3.9%
-10.5%
净利率更高
DOC
高出66.5%
-14.8%
两年增速更快
DOC
近两年复合增速
-6.6%
损益表 — Q1 FY2026 vs Q1 FY2027
| 指标 | | |
|---|---|---|
| 营收 | $702.9M | $619.8M |
| 净利润 | $363.0M | $-91.8M |
| 毛利率 | — | — |
| 营业利润率 | 0.7% | — |
| 净利率 | 51.6% | -14.8% |
| 营收同比 | -6.6% | -10.5% |
| 净利润同比 | 28.3% | — |
| 每股收益（稀释后） | $0.28 | $-1.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCQDEL
| Q1 26 | $702.9M | $619.8M | ||
| Q4 25 | $719.4M | — | ||
| Q3 25 | $705.9M | $699.9M | ||
| Q2 25 | $694.3M | $613.9M | ||
| Q1 25 | $702.9M | $692.8M | ||
| Q4 24 | $698.0M | $707.8M | ||
| Q3 24 | $700.4M | $727.1M | ||
| Q2 24 | $695.5M | $637.0M |
净利润DOCQDEL
| Q1 26 | $363.0M | $-91.8M | ||
| Q4 25 | $114.0M | — | ||
| Q3 25 | $-117.1M | $-733.0M | ||
| Q2 25 | $31.7M | $-255.4M | ||
| Q1 25 | $42.8M | $-12.7M | ||
| Q4 24 | $4.5M | $-178.4M | ||
| Q3 24 | $85.9M | $-19.9M | ||
| Q2 24 | $146.0M | $-147.7M |
毛利率DOCQDEL
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 58.6% | — | ||
| Q2 25 | 60.2% | — | ||
| Q1 25 | 61.1% | — | ||
| Q4 24 | 60.3% | — | ||
| Q3 24 | 60.0% | — | ||
| Q2 24 | 60.6% | — |
营业利润率DOCQDEL
| Q1 26 | 0.7% | — | ||
| Q4 25 | 17.4% | — | ||
| Q3 25 | 9.2% | -100.7% | ||
| Q2 25 | 5.7% | -29.4% | ||
| Q1 25 | 7.7% | 4.7% | ||
| Q4 24 | -2.2% | -14.2% | ||
| Q3 24 | 14.1% | 2.1% | ||
| Q2 24 | 22.3% | -18.4% |
净利率DOCQDEL
| Q1 26 | 51.6% | -14.8% | ||
| Q4 25 | 73.2% | — | ||
| Q3 25 | -16.6% | -104.7% | ||
| Q2 25 | 4.6% | -41.6% | ||
| Q1 25 | 6.1% | -1.8% | ||
| Q4 24 | 0.7% | -25.2% | ||
| Q3 24 | 12.3% | -2.7% | ||
| Q2 24 | 21.0% | -23.2% |
每股收益（稀释后）DOCQDEL
| Q1 26 | $0.28 | $-1.35 | ||
| Q4 25 | $0.16 | — | ||
| Q3 25 | $-0.17 | $-10.78 | ||
| Q2 25 | $0.05 | $-3.77 | ||
| Q1 25 | $0.06 | $-0.19 | ||
| Q4 24 | $0.02 | $-2.54 | ||
| Q3 24 | $0.12 | $-0.30 | ||
| Q2 24 | $0.21 | $-2.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $-1.2B | $140.4M |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $7.8B | $1.9B |
| 总资产 | $21.6B | $5.6B |
| 负债/权益比越低杠杆越低 | — | 1.33× |
8季度趋势，按日历期对齐
现金及短期投资DOCQDEL
| Q1 26 | $-1.2B | $140.4M | ||
| Q4 25 | $467.5M | — | ||
| Q3 25 | $91.0M | $98.1M | ||
| Q2 25 | $89.4M | $151.7M | ||
| Q1 25 | $70.6M | $127.1M | ||
| Q4 24 | $119.8M | $98.3M | ||
| Q3 24 | $180.4M | $143.7M | ||
| Q2 24 | $106.9M | $107.0M |
总债务DOCQDEL
| Q1 26 | — | $2.5B | ||
| Q4 25 | $9.8B | — | ||
| Q3 25 | $9.1B | $2.5B | ||
| Q2 25 | $9.0B | $2.1B | ||
| Q1 25 | $8.9B | $2.1B | ||
| Q4 24 | $8.7B | $2.1B | ||
| Q3 24 | $8.6B | $2.2B | ||
| Q2 24 | $8.6B | $2.2B |
股东权益DOCQDEL
| Q1 26 | $7.8B | $1.9B | ||
| Q4 25 | $7.5B | — | ||
| Q3 25 | $7.6B | $2.0B | ||
| Q2 25 | $7.9B | $2.8B | ||
| Q1 25 | $8.2B | $3.0B | ||
| Q4 24 | $8.4B | $3.0B | ||
| Q3 24 | $8.6B | $3.2B | ||
| Q2 24 | $8.8B | $3.2B |
总资产DOCQDEL
| Q1 26 | $21.6B | $5.6B | ||
| Q4 25 | $20.3B | — | ||
| Q3 25 | $19.6B | $5.7B | ||
| Q2 25 | $19.8B | $6.4B | ||
| Q1 25 | $19.8B | $6.5B | ||
| Q4 24 | $19.9B | $6.4B | ||
| Q3 24 | $20.0B | $6.8B | ||
| Q2 24 | $20.2B | $6.7B |
负债/权益比DOCQDEL
| Q1 26 | — | 1.33× | ||
| Q4 25 | 1.31× | — | ||
| Q3 25 | 1.20× | 1.23× | ||
| Q2 25 | 1.14× | 0.74× | ||
| Q1 25 | 1.08× | 0.70× | ||
| Q4 24 | 1.04× | 0.72× | ||
| Q3 24 | 1.00× | 0.68× | ||
| Q2 24 | 0.98× | 0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
| Outpatient Medical | $320.5M | 46% |
| Lab | $217.6M | 31% |
| Senior Housing | $148.9M | 21% |
| Other | $14.3M | 2% |
| Corporate Non-segment | $1.5M | 0% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
